Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026)
Canton Strategic Holdings posted quarterly Cash from Financing Activities of $87.0 million for Q1 2026, up 42200.79% year-on-year from N/an in Q1 2025, and down 10.76% on a QoQ basis from $97.4 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Cash from Financing Activities data on file, last reported at $87.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 42200.79% year-over-year to $87.0 million; the trailing twelve-month figure through Mar 2026 stood at $193.9 million (up 5579.56% YoY), and the FY2025 full-year result was $107.2 million, up 2939.54% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $87.0 million, down from $97.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.4 million in Q4 2025 and bottomed at -$338585.0 in Q3 2022.
- The 5-year median for Cash from Financing Activities is $1.6 million (2024), against an average of $13.1 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities tumbled 485.1%; it then surged 42200.79% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at -$193457.0 in 2022, then soared by 5094.25% to $9.7 million in 2023, then sank by 81.18% to $1.8 million in 2024, then jumped by 5257.28% to $97.4 million in 2025, then slipped by 10.76% to $87.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $87.0 million (Q1 2026), $97.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 86.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.96 Mn |
| Mar 31, 2026 | 86.96 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 205,568.00 |
| Mar 31, 2025 | 205,568.00 |
| Dec 31, 2024 | 1.82 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | -257,730.00 |
| Sep 30, 2024 | -257,730.00 |
| Jun 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 317,119.00 |
| Mar 31, 2024 | 317,119.00 |
| Dec 31, 2023 | 9.66 Mn |
| Dec 31, 2023 | 9.66 Mn |
| Sep 30, 2023 | -306,006.00 |
| Sep 30, 2023 | -306,006.00 |
| Jun 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 523,364.00 |
| Mar 31, 2023 | 523,364.00 |
| Dec 31, 2022 | -193,457.00 |
| Dec 31, 2022 | -193,457.00 |
| Sep 30, 2022 | -338,585.00 |
| Sep 30, 2022 | -338,585.00 |
| Jun 30, 2022 | -264,288.00 |
| Jun 30, 2022 | -264,288.00 |
| Mar 31, 2022 | 13.86 Mn |
| Mar 31, 2022 | 13.86 Mn |
| Dec 31, 2021 | -33,064.00 |
| Dec 31, 2021 | -33,064.00 |
| Sep 30, 2021 | 332,600.00 |
| Sep 30, 2021 | 332,600.00 |
| Jun 30, 2021 | 276,187.00 |
| Jun 30, 2021 | 276,187.00 |
| Mar 31, 2021 | 323,025.00 |
| Mar 31, 2021 | 323,025.00 |